Document Detail

Low Myocardial Protein Kinase G Activity in Heart Failure with Preserved Ejection Fraction.
MedLine Citation:
PMID:  22806632     Owner:  NLM     Status:  Publisher    
BACKGROUND: Prominent features of myocardial remodeling in heart failure with preserved ejection fraction (HFPEF) are high cardiomyocyte resting tension(F(passive)) and cardiomyocyte hypertrophy. In experimental models, both reacted favourably to raised protein kinase G (PKG) activity. The present study assessed myocardial PKG activity, its downstream effects on cardiomyocyte F(passive) and cardiomyocyte diameter and its upstream control by cyclic guanosine monophosphate (cGMP), nitrosative/oxidative stress and brain natriuretic peptide (BNP). To discern altered control of myocardial remodeling by PKG, HFPEF was compared to aortic stenosis(AS) and HF with reduced EF (HFREF). METHODS AND RESULTS: Patients with HFPEF (n=36), AS (n=67) and HFREF (n=43) were free of coronary artery disease. More HFPEF patients were obese (p<0.05) or had diabetes (p<0.05). LV myocardial biopsies were procured transvascularly in HFPEF and HFREF and perioperatively in AS. F(passive) was measured in cardiomyocytes before and after PKG administration. Myocardial homogenates were used for assessment of PKG activity, cGMP concentration, proBNP-108 expression and nitrotyrosine expression, a measure of nitrosative/oxidative stress. Additional quantitative immunohistochemical analysis was performed for PKG activity and nitrotyrosine expression. Lower PKG activity in HFPEF than in AS (p<0.01) or HFREF (p<0.001) was associated with higher cardiomyocyte F(passive) (p<0.001) and related to lower cGMP concentration(p<0.001) and higher nitrosative/oxidative stress (p<0.05). Higher F(passive) in HFPEF was corrected by in-vitro PKG administration. CONCLUSIONS: Low myocardial PKG activity in HFPEF was associated with raised cardiomyocyte F(passive) and was related to increased myocardial nitrosative/oxidative stress. The latter was probably induced by the high prevalence in HFPEF of metabolic comorbidities. Correction of myocardial PKG activity could be a target for specific HFPEF treatment.
Loek van Heerebeek; Nazha Hamdani; Inês Falcão-Pires; Adelino F Leite-Moreira; Mark P V Begieneman; Jean G F Bronzwaer; Jolanda van der Velden; Ger J M Stienen; Gerrit J Laarman; Aernout Somsen; Freek W A Verheugt; Hans W M Niessen; Walter J Paulus
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-7-17
Journal Detail:
Title:  Circulation     Volume:  -     ISSN:  1524-4539     ISO Abbreviation:  -     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-7-18     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1 VU University Medical Center & Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands;
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of safety and efficacy of the TriPollar technology for treatment of wrinkles.
Next Document:  Human TTRV30M localization within podocytes in a transgenic mouse model of transthyretin related amy...